AMAlain Le Moine

Alain Le Moine

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alain Le Moine has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Arnaud Marchant

    European Plotkin Institute for Vaccinology, Université Libre de Bruxelles, 900 Route de Lennik, 170 Anderlecht, Belgium; ULB Centre for Research in Immunology (U-CRI), Université Libre de Bruxelles, 8 Rue Adrienne Bolland, 6041 Gosselies, Belgium

    4 shared publications
  • Catalano Concetta

    Institute for Medical Immunology, Université libre de Bruxelles Charleroi Belgium; Department of Nephrology, Dialysis and Renal Transplantation, Hôpital Erasme, Université libre de Bruxelles Bruxelles Belgium

    3 shared publications
  • Margaret E. Ackerman

    Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College , Hanover, NH

    3 shared publications
  • Anne Lemy

    Department of Nephrology, Marie Curie Hospital, Charleroi, Belgium

    2 shared publications
  • Benedetta Chiodini

    Department of Pediatric Nephrology, Pediatric Nephrology, HUB-Hôpital Universitaire Des Enfants Reine Fabiola, Université Libre de Bruxelles (ULB), Brussels, Belgium

    2 shared publications
  • Charlotte Vanhomwegen

    Department of Nephrology, Hôpital Universitaire de Bruxelles-Erasme (HUB-Erasme), European Plotkin Institute for Vaccinology, Université Libre de Bruxelles (ULB), 1050 Brussels, Belgium

    2 shared publications

Latest Publications

  • Functional and phenotypic profiles of HLA-specific antibodies in relation to antibody-mediated kidney transplant rejection

    by Margaret C. Carpenter, Sweta Shrestha, Pranay Bharadwaj, Catalano Concetta, Shilpee Sharma, Joshua A. Weiner, Noortje de Haan, Tamas Pongracz, Alain Le Moine, Vanda Holovska, et al.


  • Open Access

    BK Polyomavirus in Pediatric Renal Transplantation—What We Know and What We Do Not

    by Benedetta Chiodini, Pauline Guillaume-Gentil, Charlotte Vanhomwegen, Elise Hennaut, Ksenija Lolin, Nathalie Tram, Alain Le Moine, Khalid Ismaili

    BK polyomavirus (BKPyV) is still a real threat in the management of kidney transplantation. Immunosuppressive treatment disrupts the equilibrium between virus replication and immune response, and uncontrolled BKPyV replication leads to nephropathy (BKPyV nephropathy). The first evidence of BKPyV reactivation in transplant recipients is the detection of viral shedding in urine, which appears in 20% to 60% of patients, followed by BKPyV viremia in 10–20% of kidney transplant recipients. BKPyV nephropathy eventually occurs in 1–10% of this population, mainly within the first 2 years post-transplantation, causing graft loss in about half of those patients. Few data exist regarding the pediatric population and we focus on them. In this paper, we review the existing diagnostic methods and summarize the evidence on the role of BKPyV humoral and cellular immunity in modulating the clinical course of BKPyV infection and as potential predictors of the outcome. We look at the known risk factors for BKPyV nephropathy in the immunosuppressed patient. Finally, we propose a sensible clinical attitude in order to screen and manage BKPyV infection in kidney transplant children.


  • Open Access

    BK Polyomavirus in Pediatric Renal Transplantation. What We Know and What We Don’t.

    by Benedetta Chiodini, Pauline Guillaume-Gentil, Charlotte Vanhomwegen, Elise Hennaut, Ksenija Lolin, Nathalie Tram, Alain Le Moine, Khalid Ismaili

    BK polyomavirus (BKPyV) is still a real threat in the management of kidney transplantation. Immunosuppressive treatment disrupts the equilibrium between virus replication and immune response, and uncontrolled BKPyV replication leads to nephropathy (BKPyV nephropathy). The first evidence of BKPyV reactivation in transplant recipients is the detection of viral shedding in urine, which appears in 20% to 60% of patients, followed by BKPyV viremia in 10-20% of kidney transplant recipients. BKPyV nephropathy eventually occurs in 1-10% of this population, mainly within the first 2 years post-transplantation, causing graft loss in about half of those patients. Few data exist regarding the pediatric population and we focus on them. In this paper, we review the existing diagnostic methods, we summarize the evidences on the role of BKPyV humoral and cellular immunity in the modulation of the clinical course of BKPyV infection and as potential predictors of the outcome. We look at the known risk factors of BKPyV nephropathy in the immunosuppressed patient. Finally, we propose a sensible clinical attitude in order to screen and manage BKPyV infection in kidney transplant children.


  • Open Access

    Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients

    by Delphine Kemlin, Nicolas Gemander, Stéphanie Depickère, Véronique Olislagers, Daphnée Georges, Alexandra Waegemans, Pieter Pannus, Anne Lemy, Maria E. Goossens, Isabelle Desombere, et al.


  • Open Access

    Hybrid immunity to SARS-CoV-2 in kidney transplant recipients and hemodialysis patients

    by Delphine Kemlin, Anne Lemy, Pieter Pannus, Isabelle Desombere, Nicolas Gemander, Maria E. Goossens, Arnaud Marchant, Alain Le Moine


  • Open Access

    Afucosylation of HLA-specific IgG1 as a potential predictor of antibody pathogenicity in kidney transplantation

    by Pranay Bharadwaj, Sweta Shrestha, Tamas Pongracz, Catalano Concetta, Shilpee Sharma, Alain Le Moine, Noortje de Haan, Naoka Murakami, Leonardo V. Riella, Vanda Holovska, et al.

    Summary: Antibody-mediated rejection (AMR) is the leading cause of graft failure. While donor-specific antibodies (DSA) are associated with a higher risk of AMR, not all patients with DSA develop rejection suggesting that the characteristics of alloantibodies that determine their pathogenicity remain undefined. Using human leukocyte antigen (HLA)-A2-specific antibodies as a model, we applied systems serology tools to investigate qualitative features of immunoglobulin G (IgG) alloantibodies including Fc-glycosylation patterns and Fc γ R binding properties. The levels of afucosylation of anti-A2 antibodies were elevated in all seropositive patients and were significantly higher in AMR patients, suggesting potential cytotoxicity via Fc γ RIII-mediated mechanisms. Afucosylation of both glycoengineered monoclonal and naturally glycovariant polyclonal serum IgG specific to HLA-A2 exhibited potentiated binding to, slower dissociation from, and enhanced signaling through Fc γ RIII, a receptor widely expressed on innate effector cells. Collectively, these results suggest that afucosylated DSA may be a biomarker of AMR and could contribute to its pathogenesis. Graphical Potential influence of HLA-A2-specific IgG1 afucosylation, FcγRIIIa binding and activation on ADCC and graft rejection.: Illustration created with https://BioRender.com .


  • Open Access

    Case Report: Homozygous Pathogenic Variant P209L in the TTC21B Gene: A Rare Cause of End Stage Renal Disease and Biliary Cirrhosis Requiring Combined Liver-Kidney Transplantation. A Case Report and Literature Review

    by Giuseppe Gambino, Concetta Catalano, Martina Marangoni, Caroline Geers, Alain Le Moine, Nathalie Boon, Guillaume Smits, Lidia Ghisdal

    Background: Ciliopathies are rare diseases causing renal and extrarenal manifestations. Here, we report the case of a ciliopathy induced by a homozygous pathogenic variant in the TTC21B gene.Case Description: A 47-year-old patient started hemodialysis for chronic kidney disease (CKD) of unknown origin. She presented with early onset of hypertension, pre-eclampsia, myopia and cirrhosis. Renal biopsy showed mild interstitial fibrosis, tubular atrophy, and moderate arteriosclerosis while liver pathology demonstrates grade B biliary cirrhosis. Family history revealed several cases of early-onset severe hypertension and one case of end-stage renal disease (ESRD) needing kidney transplantation at twenty years of age. Clinical exome sequencing showed homozygosis for the pathogenic variant c.626C>T (p.Pro209Leu) in the TTC21B gene. The patient underwent combined liver-renal transplantation with an excellent renal and hepatic graft outcome.Conclusions:TTC21B gene mutations can lead heterogeneous to clinical manifestations and represent an underappreciated cause of ESRD. The paradigm in diagnosis of CKD of early onset and/or of unknown origin is changing and genetic counseling should be performed in all patients and families that meet those criteria. Renal or combined liver-renal transplantation represents the best option for patients suffering from those diseases in terms of prognosis and quality of life.